Alzheimer's Disease Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight

DelveInsight's "Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Alzheimer's disease, historical and forecasted epidemiology as well as the Alzheimer's disease market trends in the United States, EU4 and the UK (Germany, France, Italy, Spain) and the United Kingdom, and Japan.

Discover which therapies are expected to grab the Alzheimer's Disease Market Share @ Alzheimer's Disease Market Outlook- https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Alzheimer's Disease Market Size Report
• In May 2025, Annovis Bio Inc. announced clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn about the safety of buntanetap/Posiphen.
• In May 2025, Hoffmann-La Roche announced clinical trial is recruiting people who either are at risk of AD - have build-up of beta-amyloid, but have no clinical symptoms, or with a diagnosis of mild cognitive impairment. People can take part if they have a certain level of plaques (beta-amyloid) in the brain, shown by a positron emission tomography (PET) scan, a medical imaging technique in which tracers are injected to visualize specific pathological processes in the brain.
• In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of Alzheimer's disease in Japan were nearly 3,920 thousand in 2023.
• In 2023, the United States represented approximately 44% of diagnosed Alzheimer's disease cases across the 7MM, with 6,980 thousand cases, a figure anticipated to increase by 2034, as per DelveInsight's estimates.
• In Japan, there were nearly 1,390 thousand diagnosed males and 2,530 thousand cases of females with Alzheimer's disease in 2023, highlighting gender distribution among the population.
• Age-specific cases in the US are categorized into four groups: under 65, 65-74, 75-84, and 85+ years. In 2023, the 75-84 age group held the highest prevalence with nearly 2,790 thousand cases, whereas the under-65 group recorded the lowest with nearly 175 thousand cases.
• Alzheimer's disease is also classified by severity: mild cognitive impairment (MCI), mild, moderate, and severe dementia. Within EU4 and the UK, the MCI stage had the highest prevalence with around 2,560 thousand cases in 2023, while severe dementia showed the lowest with 645 thousand cases.
• The US reported nearly 5,233 thousand diagnosed cases of agitation associated with Alzheimer's disease in 2023, which is expected to grow by 2034.
• In Japan, approximately 2030 thousand cases of psychosis in Alzheimer's disease were documented in 2023, a number forecasted to increase over time.
• The leading Alzheimer's Disease Companies such as AB Science, Alzheon Inc., AriBio Co., Ltd., AgeneBio, Inc., Anavex Life Sciences Corp., Annovis Bio, Inc., Cerecin, BioVie, Cassava Sciences, Novo Nordisk, Eli Lilly, Neurim Pharmaceuticals, Suven Life Sciences, Bristol Myers Squibb/Karuna Therapeutics, T3D Therapeutics, Inc., Lexeo Therapeutics, Axsome Therapeutics, Inc., Araclon Biotech S.L., Eisai Co., Ltd., TauRx Therapeutics, TrueBinding, Inc., AC Immune SA/Johnson & Johnson, Longeveron Inc., Vaccinex Inc., IGC Pharma LLC. And others.
• Promising Alzheimer's Disease Pipeline Therapies such as BAN2401, Gantenerumab, ALZT-OP1, Bryostatin-1, ALZT-OP1, Tricaprilin and others.

Stay ahead in the Alzheimer's Disease Treatment Market with DelveInsight's Strategic Report @ M Alzheimer's Disease Market Outlook- https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Alzheimer's Disease Epidemiology Segmentation in the 7MM
• Total Alzheimer's Disease Diagnosed Prevalent Cases
• Alzheimer's Disease Age-specific Cases
• Alzheimer's Disease Gender-specific Cases
• Alzheimer's Disease Severity-specific Cases

Download the report to understand which factors are driving Alzheimer's Disease Epidemiology trends @ Alzheimer's Disease Prevalence- https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Alzheimer's Disease Marketed Drugs
• LEQEMBI (lecanemab): Biogen Inc./Eisai Co., Ltd.
LEQEMBI, an FDA-approved treatment for Alzheimer's, specifically targets patients in the Alzheimer's disease or mild dementia stages. Developed as a humanized IgG1 monoclonal antibody, LEQEMBI addresses amyloid ß (Aß) pathology by reducing both soluble and insoluble forms of Aß to slow disease progression. With ongoing prescription expansion, the focus includes customized facility information on the drug, reimbursement support, and system efficiency enhancements. Approved by regulatory bodies in Great Britain (August 2024) and Japan (September 2023), LEQEMBI marks a significant milestone as the first approved therapy in Europe to target an Alzheimer's-related pathology directly.

• KISUNLA (Donanemab): Eli Lilly and Company
KISUNLA (donanemab-azbt), developed by Eli Lilly, targets amyloid plaques in patients with Alzheimer's disease or early symptomatic Alzheimer's disease confirmed by amyloid pathology. This humanized IgG1 monoclonal antibody addresses amyloid ß accumulation-a key contributor to Alzheimer's by focusing on insoluble N-truncated pyroglutamate amyloid beta plaques. Administered intravenously every four weeks, KISUNLA's structured dosing regimen was informed by Phase III TRAILBLAZER-ALZ 2 trial data, supporting approvals in the US (July 2024) and Japan (September 2024). Unique to KISUNLA is the potential to halt treatment once plaques clear, which may optimize efficacy and lower treatment costs.

Emerging Alzheimer's disease Drugs
• Masitinib (AB1010): AB Science
Masitinib, an orally administered tyrosine kinase inhibitor, targets neuro-immune cells such as mast cells and microglia that accumulate in the Central Nervous System (CNS) at effective concentrations. Evidence increasingly links these cells to Alzheimer's disease pathology. In preclinical studies, masitinib demonstrated synaptic protection by inhibiting mast cells, which contributed to improved spatial learning and recovery of synaptic markers in Alzheimer's disease models. The drug is currently in Phase III clinical trial and development for the disease.

• Valiltramiprosate (ALZ-801): Alzheon, Inc.
ALZ-801 is an oral small-molecule prodrug that effectively blocks the formation of neurotoxic amyloid oligomers in the brain. Structurally, it is a valine-conjugated version of tramiprosate, metabolizing into homotaurine in the body, which enhances absorption and extends blood retention compared to tramiprosate. Both ALZ-801 and tramiprosate are metabolized to 3-sulfopropanoic acid (3-SPA), a natural brain compound that prevents Aß42 aggregation. ALZ-801 was specifically designed to improve tramiprosate's gastrointestinal tolerance and pharmacokinetics, allowing for efficient gut absorption and conversion to active tramiprosate in the bloodstream. Phase I studies indicate improved gastrointestinal tolerance and stable plasma levels.

• Tricaprilin (CER-0001): Cerecin
Cerecin's tricaprilin (CER-0001) (also known as AC-1204) is an innovative oral formulation of caprylic triglyceride, designed to induce a mild state of chronic that enhances mitochondrial metabolism. Early in the progression of Alzheimer's disease, there is a notable decline in cerebral glucose utilization. Tricaprilin aims to counteract this by providing an alternative energy source for cells, thus boosting metabolic activity in Alzheimer's disease. Caprylic acid is converted into bodies, including acetoacetic acid and ß-hydroxybutyric acid, which can then be transformed into acetyl-CoA, facilitating energy production through the citric acid cycle.

• Bezisterim (NE3107): BioVie
NE3107 is an oral small molecule designed to effectively penetrate the blood-brain barrier, serving as both an anti-inflammatory agent and an insulin sensitizer. It selectively targets Extracellular Signal-regulated Kinase (ERK) to inhibit inflammatory pathways by blocking ERK/NF?B activation and decreasing tumor necrosis factor (TNF) production, particularly in response to inflammatory stimuli such as lipopolysaccharides. This mechanism holds promise for reducing pathological inflammatory signaling in peripheral tissues and the Central Nervous System (CNS), potentially alleviating insulin resistance, diminishing inflammatory cell infiltration in the CNS, and modulating microglial activation without impairing their critical functions.

To learn more about Alzheimer's Disease treatment guidelines, visit @ Alzheimer's Disease Treatment Market Landscape- https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Alzheimer's Disease Companies
AB Science, Alzheon Inc., AriBio Co., Ltd., AgeneBio, Inc., Anavex Life Sciences Corp., Annovis Bio, Inc., Cerecin, BioVie, Cassava Sciences, Novo Nordisk, Eli Lilly, Neurim Pharmaceuticals, Suven Life Sciences, Bristol Myers Squibb/Karuna Therapeutics, T3D Therapeutics, Inc., Lexeo Therapeutics, Axsome Therapeutics, Inc., Araclon Biotech S.L., Eisai Co., Ltd., TauRx Therapeutics, TrueBinding, Inc., AC Immune SA/Johnson & Johnson, Longeveron Inc., Vaccinex Inc., IGC Pharma LLC. And others

Alzheimer's Disease Market Outlook
Currently, available therapies for Alzheimer's disease primarily target symptom management by modulating key neurotransmitters, including acetylcholine, serotonin, and noradrenaline, while aiming to reduce the activity of glutamate and dopamine. However, these approaches often lead to potential side effects, highlighting the necessity for personalized treatment strategies that consider patient comorbidities and potential drug interactions. Recent approvals, such as LEQEMBI (lecanemab) by Biogen and Eisai, Eli Lilly's KISUNLA (donanemab-azbt), and Brexpiprazole (REXULTI), signify a shift toward more tailored therapeutic options.

Learn more about the FDA-approved drugs for Alzheimer's Disease @ Drugs for Mantle Cell Lymphoma Treatment- https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Alzheimer's Disease Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Alzheimer's Disease Companies- AB Science, Alzheon Inc., AriBio Co., Ltd., AgeneBio, Inc., Anavex Life Sciences Corp., Annovis Bio, Inc., Cerecin, BioVie, Cassava Sciences, Novo Nordisk, Eli Lilly, Neurim Pharmaceuticals, Suven Life Sciences, Bristol Myers Squibb/Karuna Therapeutics, T3D Therapeutics, Inc., Lexeo Therapeutics, Axsome Therapeutics, Inc., Araclon Biotech S.L., Eisai Co., Ltd., TauRx Therapeutics, TrueBinding, Inc., AC Immune SA/Johnson & Johnson, Longeveron Inc., Vaccinex Inc., IGC Pharma LLC. And others.
• Alzheimer's Disease Pipeline Therapies- BAN2401, Gantenerumab, ALZT-OP1, Bryostatin-1, ALZT-OP1, Tricaprilin and others.
• Alzheimer's Disease Market Dynamics: Alzheimer's Disease Market Drivers and Barriers
• Alzheimer's Disease Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Alzheimer's Disease Drugs in development @ Alzheimer's Disease Clinical Trials Assessment- https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Key Insights
2. Report Introduction
3. Alzheimer's disease Market Overview at a Glance
4. Methodology of Alzheimer's disease Epidemiology and Market
5. Alzheimer's Disease Executive Summary
6. Key Events
7. Disease Background and Overview
8. Alzheimer's Disease Patient Journey
9. Alzheimer's Disease Epidemiology and Patient Population
10. Alzheimer's Disease Marketed Drugs
11. Alzheimer's Disease Emerging Drug Profiles
12. Alzheimer's disease: Market Analysis
13. Key Opinion Leaders' Views
14. Alzheimer's Disease SWOT Analysis
15. Alzheimer's Disease Unmet Needs
16. Alzheimer's Disease Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

List of Top Selling Market Research Reports in 2025

CAR-T Pipeline- https://www.delveinsight.com/report-store/car-t-pipeline-insight
Cystic Fibrosis Market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
Indwelling Catheters Market- https://www.delveinsight.com/report-store/urinary-catheters-market
Ly3454738 Drug Insight- https://www.delveinsight.com/report-store/moderate-to-severe-atopic-dermatitis-pipeline-insight
NK Cell Therapy Market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
Periodontal Disease Market- https://www.delveinsight.com/report-store/periodontal-disease-market
Scoliosis Market- https://www.delveinsight.com/report-store/scoliosis-market
Urea Cycle Disorders Market- https://www.delveinsight.com/report-store/urea-cycle-disorders-pipeline-insight
Attention Deficit Hyperactivity Disorder Market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Cardiac Implantable Electronic Devices Market- https://www.delveinsight.com/report-store/cardiac-implantable-electronic-devices-cieds-market
Positive Airway Pressure Device Market- https://www.delveinsight.com/report-store/positive-airway-pressure-device-market
Surgical Energy Instruments Market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market
Thrombectomy Devices Market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
Cardiac Monitoring Devices Market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
Hip Replacement Devices Market- https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
Medical Marijuana Market- https://www.delveinsight.com/report-store/medical-marijuana-market
Total Knee Arthroplasty Market- https://www.delveinsight.com/report-store/knee-reconstruction-devices-market
Healthcare Competitive Benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Lice Infestations Market- https://www.delveinsight.com/report-store/lice-infestations-pipeline-insight
Lactose Intolerance Market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Antibody Drug Conjugate Market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Sepsis Market- https://www.delveinsight.com/report-store/sepsis-market-insight
Surgical Mask & Respirator Market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: +91-9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.